Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Germany's MorphoSys is paying $1.7 billion in cash to acquire Cambridge, Mass.-based Constellation Pharmaceuticals, picking up Phase 3 BET inhibitor pelabresib…
In the Phase 2 MANIFEST trial, pelabresib in combination with ruxolitinib in JAK-inhibitor-naïve myelofibrosis (Arm 3, n=84) produced SVR35 at week 24 in…
MANIFEST-3 (NCT07357727; Novartis ref CDAK539A12303): Phase 3 randomized double-blind study of pelabresib (now branded DAK539) plus ruxolitinib vs placebo plus…
Source summaries from our enrichment pipeline; follow links for originals.
All 15 sources with sentiment breakdown →
MorphoSys agreed to acquire Constellation Pharmaceuticals for $34.00 per share (~$1.7B total equity value). Lead assets include Phase III BET inhibitor pelabresib for myelofibrosis and Phase II EZH2 inhibitor CPI-0209. Royalty Pharma provided $1.425B in funding to support the transaction.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| MorphoSys AG / Constellation Pharmaceuticals, Inc. (this deal) | 2021 | $1.7B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals | 2013 | $886M | 79 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
← Browse all deals · How we score deals
More: 2021 deals · Hematology deals